0714/25SCR019-18/R10RGB
Media Highlights
From the 2025 ASCO® Annual Meeting
6
Media Outlet Article / Coverage
American Journal of Managed
Care
March Toward More Tailored Treatments Continues at ASCO
2025
American Journal of Managed
Care
Assay Finds Patients Who Will Benefit From Adjuvant
Chemotherapy in Early-Stage NSCLC
Audio Journal of Oncology Patients with Early-Stage Non-Squamous Non-Small Cell
Lung Cancer Who can Benefit from Adjuvant Chemotherapy
The ASCO Post David R. Spigel, MD, FASCO, on NSCLC Treatment Planning:
Role of 14-Gene Molecular Assay
The ASCO Post Molecular Assay Identifies Patients With Early NSCLC Likely
to Benefit From Adjuvant Chemotherapy
Cure Targeted Chemo Improves Survival in Early-Stage Lung
Cancer
eCancer Molecular Assay May Help Identify NSCLC Patients Who
Could Benefit From Adjuvant Chemotherapy
Endpoints News As Life-Saving Checkpoint Drugs Move to Earlier Cancers,
Researchers Debate How Best to Use Them
Endpoints News BioNTech Presents Impressive Early Data for PD-L1xVEGF in
Mesothelioma
GenomeWeb ASCO: Razor Genomics Test Shows Promise for
Chemotherapy Selection in High-Risk Lung Cancer Patients
Healio/HemOnc Today Assay Predicts Adjuvant Chemotherapy Benefit in Early-
Stage Non-Small Cell Lung Cancer
HealthDay American Society of Clinical Oncology, May 31-June 3
JNCCN 360 David R. Spigel, MD, FASCO, on Guiding Adjuvant
Chemotherapy Using a Molecular Assay
MedPage Today Gene-Driven Adjuvant Therapy for NSCLC Leads to Big
Improvement in DFS
David Spigel, MD
SCRI
Continued ➔
